Scalable technology for the extraction of pharmaceutics: outcomes from a 3 year collaborative industry/academia research programme.

摘要: Abstract This paper reports on some of the key outcomes a 3 year £1.5 m Technology Strategy Board (TSB) funded research programme to develop small footprint, versatile, counter-current chromatography purification technology and methodology which can be operated at range scales in both batch continuous modes that inserted into existing process plant systems. Our consortium, integrates providers (Dynamic Extractions) scientific development team (Brunel) with end user needs (GSK & Pfizer), addressing major production challenges aimed providing flexible, low capital platform driving substantial cost efficiency drug manufacturing processes. The aims Board's high value are described how academic/industry community were challenged instigate step changes pharmaceuticals. focusses one themes TSB programme, “Generate Comprehensive Applications Portfolio”. It outlines 15 applications from this portfolio published public domain gives four detailed case studies illustrating application separation (1) isomers, (2) polar compounds, (3) crude mixtures (4) removal impurities. Two these scaled up demonstrate between 10 20% lower solvent usage projected have significant savings compared conventional solid phase silica gel procss scale demonstrating latest performance countercurrent is competitive technolgy for pharmaceutical industry.